We are thrilled to announce that Dr. Patrick Taus has been awarded a prestigious Vasculitis Foundation Research Grant to support a bold new project that targets one of the root causes of ANCA-associated vasculitis, a devastating autoimmune disease that frequently leads to kidney damage and failure. Congratulations for this well-deserved recognition and for pushing the boundaries of nephrology and vasculitis research!
Why This Research Matters
Anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis occurs when the immune system mistakenly attacks proteins inside neutrophils, key infection-fighting white blood cells. In most patients, these attacks are directed against either proteinase 3 (PRTN3) or myeloperoxidase (MPO), leading to destructive inflammation of small blood vessels. The kidneys are among the organs most commonly and severely affected.
Although current immunosuppressive therapies can bring about remission in the majority of patients, they come at a high cost—leaving patients vulnerable to infection, steroid-related complications, and even cancer. Clearly, there is an urgent need for safer and more targeted treatments.
The Project’s Ams
This project focuses on PRTN3 itself—the main autoantigen in ANCA vasculitis—rather than broadly suppressing the immune system. Targeting PRTN3 directly could lead to the first ANCA-specific therapies—treatments that reduce disease activity without compromising the body’s entire immune defense.
The Vasculitis Foundation’s support ensures that this bold, high-impact work can move forward, advancing our understanding of the disease and bringing us closer to precision therapies that transform patient outcomes.